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OBJECTIVES: To examine incidence, prevalence and mortality rates among opioid-
dependent patients in the U.S. Medicare population. METHODS: A study was per-
formed for the period from January 1, 2008 through December 31, 2012 to determine 
the prevalence, incidence and mortality rates among opioid-dependent patients 
(International Classification of Diseases, 9th Revision, Clinical Modification diag-
nosis codes 304.0x and 304.7x) in the U.S. Medicare population. Patients who had 
continuous fee-for-service Medicare health plan enrollment for the calendar year 
and at least 2 years prior were selected for the study. Age- and gender-adjusted 
opioid dependence prevalence and incidence rates were calculated via direct stand-
ardization to the U.S. population age ≥ 65 years in 2010 using gender-specific age 
groups. RESULTS: The annual adjusted prevalence of opioid-dependent patients 
increased from 0.06% in 2008 to 0.35% in 2012. Incidence rates increased from 0.06% 
in 2008 to 0.10% in 2012. Prevalence rates were higher among women than men every 
year during the study period. Patients age 65-69 years had the highest prevalence 
rates during 2008 (0.09%), 2009 (0.16%), 2010 (0.22%) and 2011 (0.32%). However, in 
2012, patients who were age 70-74 years had the highest prevalence rates (0.43%). 
North American Natives had the highest prevalence of opioid dependence compared 
to all other races. The highest incidence of opioid dependence was observed in 
Nevada in 2008 (221.9 per 100,000 person-years) and 2012 (222.1 per 100,000 person-
years). The 30-day and 1-year mortality rates decreased by 10.5% (3.8 to 3.4 per 1,000 
person-years) and 25.4% (17.3 to 12.9 per 1,000 person-years), respectively, from 2008 
to 2012. CONCLUSIONS: Opioid dependence incidence and prevalence decreased 
from 2008 to 2012; however, opioid dependence-related mortality rates increased.
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OBJECTIVES: Given the lack of research on this in China, treatment guidelines for 
major depressive disorder (MDD) have been adapted based on Western guidelines. 
This study assessed health outcomes of MDD-diagnosed and MDD-undiagnosed 
vs. non-depressed respondents in urban China. METHODS: Data were obtained 
from the 2012 China National Health and Wellness Survey, a mixed-methodology, 
internet-based, nationwide survey of adults (18+ years) stratified by gender and 
age to represent the demographic composition of urban China. Respondents self-
reporting physician diagnosis of depression and screening positive for MDD based 
on Patient Health Questionnaire-9 (PHQ-9) scores (n= 97), plus those screening 
positive for MDD but undiagnosed and not experiencing depression (n= 1,005) were 
compared with non-depressed respondents (n= 17,022). Undiagnosed respondents 
were further compared across MDD severity levels (moderate, moderately severe, 
severe). Outcomes included: SF-36v2-based mental (MCS) and physical (PCS) 
component summary scores and SF-6D health utilities; Work Productivity and 
Activity Impairment questionnaire-based metrics; and resource utilization (past 
six months). Regression models assessed health outcomes as a function of MDD, 
controlling for demographics and comorbidities. RESULTS: MDD prevalence was 
6.0%, with 8.3% of MDD-screened respondents diagnosed with depression, among 
whom 51.5% currently used prescription medication for depression. After adjust-
ment, diagnosed and undiagnosed MDD respondents had lower health utilities 
and PCS and MCS (diagnosed-MDD: 32.8; undiagnosed-MDD: 37.1; non-depressed: 
46.9) scores, plus greater absenteeism, presenteeism, overall work impairment 
(diagnosed-MDD: 47.1%; undiagnosed-MDD: 46.4%; non-depressed: 23.0%), activity 
impairment, emergency room visits (diagnosed-MDD: 0.95; undiagnosed-MDD: 0.72; 
non-depressed: 0.32), hospitalizations, and traditional provider visits, compared 
with non-depressed respondents, all p< 0.01. Severe vs. moderate undiagnosed-
MDD respondents had lower MCS and PCS and 1.4 times as many provider visits 
(all p< 0.05). CONCLUSIONS: Over 90% of MDD-screened respondents were undiag-
nosed. MDD sufferers in urban China may be under-diagnosed and undertreated. 
Awareness and better access to treatments may help alleviate the burden associ-
ated with MDD.
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OBJECTIVES: To examine incidence and prevalence rates among alcohol-dependent 
patients in the U.S. Medicare population. METHODS: A prospective study was per-
formed from 01JAN2008 through 31DEC2012 to determine the prevalence and inci-
dence of patients diagnosed with alcohol dependence (International Classification 
of Diseases, 9th Revision, Clinical Modification diagnosis code 303) in the U.S. 
Medicare population. Patients were required to have continuous enrollment in a 
fee-for-service Medicare health plan during the calendar year and at least 2 years 
prior. The age- and gender-adjusted prevalence and incidence (overall and age- 
and gender-specific) rates of alcohol-dependent patients were calculated by direct 
standardization to the U.S. population age ≥ 65 years in 2010. RESULTS: The annual 
adjusted overall prevalence rate increased from 0.30% in 2008 to 1.05% in 2012, 
whereas the annual overall incidence rate decreased from 0.30% in 2008 to 0.20% 
in 2012. Alcohol dependence prevalence and incidence rates were higher among 
men than women every year. Patients age 65-69 years had the highest prevalence 
rates during 2008 (0.43%) and 2009 (0.63%), whereas in 2010 (0.82%), 2011 (1.14%) and 
2012 (1.43%), patients age 70-74 years had the highest prevalence rates. Prevalence 
rates grew steadily among all age groups from 2008 to 2012. The highest alcohol 
dependence incidence rate was observed in the Virgin Islands (917.6 per 100,000 
person-years) in 2008, whereas in 2012, Wyoming (409.3 per 100,000 person-years) 
had the highest incidence rate. CONCLUSIONS: Increasing prevalence and decreas-
ing incidence of alcohol dependence was observed from 2008 to 2012. In addition, 
men were more likely to have alcohol dependence than women.
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OBJECTIVES: Estimating the trends in the prevalence of dementia has been a chal-
lenge because it has been relying on self-reported information in the national repre-
sentative surveys or based on diagnosis alone in community-based studies. With the 
aging of population, it is still unclear if there were any time trends in the prevalence 
of dementia. The objective of this study is to investigate the national trends in the 
prevalence of dementia using combined sources of information. METHODS: A trend 
analysis was performed using data from the Medicare Current Beneficiary Survey 
(MCBS) 2001-2010. The study sample consisted of Medicare beneficiaries aged 65 
or older. Dementia was determined based on the self-reported diagnosis, or having 
diagnosis codes in Medicare claims, or utilization of dementia-targeted prescription 
medications identified in self/proxy’s report. Cross-sectional weights were used to 
adjust for the complex survey design of MCBS. RESULTS: The prevalence of demen-
tia increased approximately 20% from 8.3% in 2001 to 10.4% in 2010 (p< .001). This 
increasing time trends were largely explained by the increase in the prevalence of 
dementia in the community setting. The prevalence remained stable in the long-
term care facilities, but increased from 4.8% to 7.3% in the community settings over 
time. We also observed the increase in the prevalence of dementia across age, sex 
and race groups. The prevalence of dementia was lower among Medicare beneficiar-
ies aged 65-75 years vs. 75 years and older, among whites vs. blacks and Hispanics, 
and in women vs. men. CONCLUSIONS: Our findings suggested the increase in the 
prevalence of dementia existing among elderly from 2001 to 2010.
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OBJECTIVES: Prenatal alcohol ingestion predisposes fetus to long term neuro-
developmental defects, yet limited studies have been done to assess its prevalence 
in Ghana. This study determined the prevalence and factors associated with the 
practice in the coastal town of Accra. METHODS: A cross sectional analytic study 
was conducted. Two hundred and forty nine pregnant women were randomly sam-
pled in James town Accra. Structured questionnaires administered to participants. 
Information gathered include prenatal alcohol consumption status, socio-economic 
status, knowledge on effects of prenatal alcohol ingestion, types of alcoholic 
beverages ingested and reasons for ingestion. Data was managed in EPI INFO 7, 
using prevalence Odds Ratio to estimate association between variables. RESULTS: 
Prevalence of Prenatal alcohol consumption was 47.4 percent. The age ranged 18 
– 48 with mean, median and modal ages as 25.7 ± 6.7, 25 and 18 years respectively. 
Among prenatal alcohol consumers, age ranged 18-48; mean, median and mode 
were 25.9 ± 6.6, 25 and 18 years respectively. The monthly income among respond-
ents ranged GHS 0.00 – 2000 (USD 0.00-625) with 120.00 (USD 37.50) as median 
income and modal monthly income 0.00 (USD 0.00). The types of alcoholic bever-
ages ingested included Beer (58%), Pito (16.7%), and Gin (10.8%). Bivariate analysis 
showed that participants who belong to religious group other than Christianity 
and Muslim (OR= 10.9 CI 2.47-48.01), having less than Junior High School education 
(OR= 2.07 CI 1.25-3.44) was associated with prenatal alcohol ingestion, however age 
(OR= 1.08 CI 0.65-1.79), having spouse or not (OR= 1.00), employment status (OR= 1.68 
CI 0.90-3.14) were not significantly associated with alcohol consumption. Reasons 
for pre-natal alcohol ingestions includes socialization or peer pressure (31.7 per-
cent), as appetizer (19.2 percent), to relieve stress (12.5 percent) and for happiness 
(10.8 percent). CONCLUSIONS: Prevalence of prenatal alcohol ingestion is high and 
associated with inadequate information. It is imperative to develop health promo-
tion strategy to address it.
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OBJECTIVES: Depression is one of the most common mental disorders in the general 
population, and may be of particular importance in Japan, which has the 7th highest 
suicide rate globally. However, depressed patients are underdiagnosed and under-
treated in the general population. We aimed to evaluate the prevalence of depression 
in the general Japanese population and the relationship of socioeconomic status 
(SES) factors with that disease. METHODS: This was a cross-sectional study. We 
used a population weighted random sample from a nationally representative panel 
of adults (≥ 20 years). A baseline questionnaire was used to capture demographic 
data, lifestyle habits, and SES parameters including family income, education level, 
and type of family. Depression was defined as a score of > 9 on the Patient Health 
Questionnaire (PHQ-9). RESULTS: 3,722 people were included in this study (mean 
age, 52 years old (SD, 18); 1,758 (47.2%) men.) The prevalence of depression was 27.1% 
(n= 1,007), among whom 55 (5.5%) were already diagnosed with depression and 605 
(60%) was women. Using multivariate logistic regression, for men, the risk factors 
for depression included lower educational attainment (OR: 1.3), low family annual 
income (< $30,000, OR: 2.3), and past history of depression (OR: 3.8). On the other 
hand, for women, they included obesity (BMI ≥ 25 kg/m2, OR: 1.5) and past history of 
depression (OR: 5.4) and SES was not associated with depression. CONCLUSIONS: 
Depressive disorders are highly prevalent in the Japanese general population. SES 
including education level and family annual income are not associated with women 
depression but with men depression.
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OBJECTIVES: Emergency room (ER) visits are perceived with the high costs and 
unpredictable outcomes. Although the association between Attention Deficit 
Hyperactivity Disorder (ADHD), stimulants and ER visits has been studied; differ-
ence between the types of stimulants in terms of risk of ER visits have not been 
studied. Our objective is to identify the difference between the effects of long act-
ing and short acting stimulant use in ADHD on ER visits in 18 to 35 year old adults 
(n= 636) in the year 2011. METHODS: This retrospective secondary data analysis 
used the Medical Expenditure Panel Survey (MEPS) data for the year 2011. Univariate 
and Multivariate logistic regression were used to evaluate risk factors influencing 
type of stimulant use on ER visits. Risk factor and stimulant interactions were also 
included. RESULTS: The risk of ER visits in long acting stimulant users, among 
the uninsured, on adjusting for race, marital and insurance status, is 14.25 times 
(p= 0.001) the risk of ER visits in short acting stimulant users. If they are insured, 
the risk of ER visits in long acting stimulant users is 1.83 times the risk of ER visits 
in short acting stimulant users (p= 0.26). CONCLUSIONS: Long-acting stimulants 
combined with lack of insurance is a risk factor for increased ER visits. Our results 
support Affordable Care Act’s efforts for the requirements of expansion on coverage 
in mental disorders to reach better healthcare outcome.
Mental HealtH – cost studies
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OBJECTIVES: The long-acting injectable aripiprazole once-monthly 400 mg (AOM 
400) has been approved for treatment of schizophrenia in Finland since November 
2013. Other atypical anti-psychotics, risperidone, paliperidone and olanzapine are 
also available as long-acting injectable formulations. A mixed treatment comparison 
has demonstrated that AOM 400 is at least as efficacious as other atypical long-
acting anti-psychotics (ALAIs). However, cost of administration and drug (treatment 
cost) vary among the ALAIs. This analysis aims to investigate the total treatment 
costs of ALAIs using real-world data in Finland. METHODS: A one-year time horizon 
budget impact analysis was conducted to compare the treatment costs of ALAIs in 
Finland. The real-world doses were calculated using sales data. One of the ALAIs 
(olanzapine) can be given in intervals of 2 or 4 weeks using the 300 mg strength. Half 
of the patients were assumed treated with the 300 mg dose every 2 weeks, the other 
half every 4 weeks. Prices for ALAIs were obtained from the official national price 
list. The cost of administration for AOM 400, paliperidone-LAI and risperidone-LAI 
was based on the cost of a short nurse visit (30 minutes) to a psychiatry outpatient 
clinic. The cost of administration of olanzapine-LAI was based on the cost of a longer 
visit (120-180 minutes), as the product information recommends monitoring for 
three hours after injection. RESULTS: The expected cost for drug and administration 
per patient, per year, for AOM 400 is 5158 EUR. The expected yearly costs per patient 
for drug and administration for paliperidone-LAI, risperidone-LAI and olanzapine-
LAI are 6021 EUR, 6706 EUR and 11646 EUR respectively. CONCLUSIONS: In a budget 
impact analysis, using the method, data and assumptions described, AOM 400 is 
expected to be cost saving, in the real-world setting, in terms of cost of drug and 
administration, compared to other ALAIs available in Finland.
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OBJECTIVES: To compare healthcare utilization and costs between early- and 
late-stage Alzheimer’s disease (AD) patients residing in long-term care (LTC) 
facilities. METHODS: Patients diagnosed with AD (International Classification of 
Diseases, 9th Revision, Clinical Modification [ICD-9-CM] code 331.0) were identified 
using U.S. Medicare claims linked with the Long-Term Care Minimum Data Set (MDS) 
from 01JULY2008 through 31DEC2010. The first diagnosis date was designated as 
the index date. Patients were required to be age ≥ 65 years, with continuous medical 
and pharmacy benefits for 6 months pre- and post-index date, and reside in an LTC 
facility. Patients were categorized as early- or late-stage. Late-stage AD was defined 
by a cognitive performance scale score ≥ 5 (range 0-6) and Activities of Daily Living 
short-form activities score ≥ 10 points. Patients with and without AD were matched 
based on demographic and clinical characteristics, and 1:1 propensity score match-
ing was used to compare follow-up all-cause and AD-related healthcare costs and 
utilizations. RESULTS: Before matching, late-stage AD patients (n= 5,323) were less 
likely to be white (83.0% vs. 86.4%), male (16.4% vs. 21.7%) and have comorbid condi-
tions measured by the Charlson Comorbidity Index score (3.55 vs. 4.83, p< 0.001) than 
early-stage AD patients (n= 20,023). After 1:1 matching, 3,804 patients were matched 
from each cohort and baseline characteristics were balanced. Fewer late-stage AD 
patients had skilled nursing facility admissions (25.3% vs. 29.8%, p< 0.0001), but more 
had hospice admissions (17.8% vs. 7.3%, p< 0.0001) and pharmacy visits (85.8% vs. 
81.9%, p< 0.0001) than early-stage AD patients. There were no significant differences 
in total all-cause healthcare costs; however, late-stage AD patients incurred signifi-
cantly higher disease-related total ($14,739 vs. $13,673, p= 0.0242) and hospice costs 
($4,157 vs. $1,553, p< 0.0001) compared to early-stage AD patients. CONCLUSIONS: 
Patients with late-stage AD incurred higher disease-related costs than those with 
early-stage AD; however, there were no significant differences in total all-cause 
healthcare costs.
PMH22
coMParative analysis of PrescriPtion utilization and costs of 
lurasidone and ariPiPrazole: a PHarMacy-database study
Ng-Mak D.S.1, Brook R.A.2, Rajagopalan K.1, Taitel M.S.3, Lou Y.3, Loebel A.4
1Sunovion Pharmaceuticals, Inc, Marlborough, MA, USA, 2Better Health Worldwide, 
Newfoundland, NJ, USA, 3Walgreen Co, Deerfield, IL, USA, 4Sunovion Pharmaceuticals, Inc, Fort 
Lee, NJ, USA
OBJECTIVES: Pharmacy databases can yield important information about drug uti-
lization and costs. This study sought to examine changes in prescription utilization 
and costs among atypical antipsychotic (AAP) subjects initiating lurasidone or ari-
piprazole therapy. METHODS: Adults filling lurasidone or aripiprazole prescriptions 
from 2/3/2011—6/30/2013 were identified in the Walgreens pharmacy-database. 
Treatment-naive monotherapy subjects (no AAP prescriptions before-and-after 
index prescription) with ≥ 12-months pre-/post-index continuous enrollment 
were eligible. Lurasidone subjects were compared to a 1:1 matched random sam-
ple of aripiprazole subjects. Baseline demographics and health-insurance status 
were compared between cohorts. Mental-health prescriptions (antianxiety agents, 
antidepressants, antipsychotics, psychotherapeutic, and neurologic agents) were 
identified using Generic Product Identifier for the National Drug Code numbers on 
pharmacy claims. Differences in mean changes (post-pre) in all-cause prescrip-
tion fills all-cause prescription costs, mental-health prescription fills and mental-
health costs were compared using t-tests. RESULTS: Each cohort included 4,595 
subjects (lurasidone vs aripiprazole: 69.3% vs 72.2% female, mean ages 41.0 vs 43.4 
years). Most subjects were commercially-insured (39.9% vs 48.6%), followed by State-
Medicaid (24.4% vs 18.7%), Medicare-Part-D (22.8% vs 18.7%), and Managed-Medicaid 
(6.8% vs 5.6%). Lurasidone subjects had lower 30-day equivalent co-pays ($42.02 vs 
$56.63). Subjects were more likely to be prescribed lurasidone by psychiatrists (78.0% 
vs 57.3%) and less likely by general-practitioners (3.1% vs 23.0%). Overall, lower 
mean increases in all-cause prescription fills (11.3 vs 12.3;p= .09) and mental-health 
prescription fills (7.2 vs 8.0;p< .01) were observed for lurasidone than aripiprazole 
subjects. Additionally, mean differences in all-cause prescription costs ($2,388 vs 
$3,080;p< .01) and mental-health prescription costs ($2,123 vs $2,810;p< .01) were 
lower for lurasidone than aripiprazole subjects. Similar patterns of mean changes in 
prescription utilization and costs were found in commercial, Medicaid and Medicare 
subjects. CONCLUSIONS: In this national-US pharmacy-database analysis compar-
ing subjects initiating branded AAPs, lurasidone subjects had fewer mean changes in 
all-cause and mental-health prescriptions and lower mean increases in associated 
costs than aripiprazole subjects.
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OBJECTIVES: Dementia is associated with high costs of national healthcare in 
European countries. Disruptive neuropsychiatric symptom (NPS) such as agitation 
and aggression (A/A), increase caregiver burden, lead to premature institutionaliza-
tion and death, and increase dementia costs. The aim of this study is to estimate 
the incremental societal costs for Patients with Dementia (PwD) with A/A in both 
Community-Dwelling (CD) and long-term care (LTC) settings in 8 European coun-
tries. METHODS: This study uses data fromthe RightTimePlaceCare (RTPC) European 
project. Interviews using structured questionnaires are conducted with 2014 PwD 
and their primary informal caregivers. Direct and informal costs are estimated from 
a societal perspective. Resource utilization is assessed with the resource utilization 
in dementia instrument. Resource consumption is valued using unit costs for each 
country, the replacement cost approach (informal care) and retail prices (medica-
tion).To estimate incremental costs of A/A, costs for PwD with A/A are compared 
to costs for PwD without A/A in both settings. Special emphasis is placed on the 
main predictors of costs. RESULTS: 2002 patients completed agitation item into 
the NeuroPsychiatric Inventory-Questionnaire at baseline (i.e. 1219 CD and 883 
LTC). For CD patients with A/A societal costs are 2,472€ for one month vs. 2,144€ 
for patient without A/A (p= 0.002). Incremental costs of A/A for CD patients are 
mainly due to informal costs and inpatient costs which are+174€ (p= 0.015) and 
+113€ (p= 0.048), respectively. For LTC patients with A/A societal costs are 4,730€ for 
one month vs. 4,166€ for patients without A/A (p= 0.003). Incremental costs of A/A 
for LTC patients are mainly due to nursing home costs and outpatient costs which 
are +353€ (p= 0.003) and +148€ (p= 0.000), respectively. CONCLUSIONS: A/A in PwD 
living at home or in LTC setting increase societal costs by 15%.
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OBJECTIVES: Schizoaffective disorder, with both mood and psychotic symptoms, 
may necessitate different treatment than other schizophrenia subtypes. Long-
acting injectable antipsychotics may reduce hospitalizations among schizophrenia 
patients but generalizability to schizoaffective disorder is unclear. This study com-
